Dolores R.
- Country
- Spain
- Department
- Nephrology department, Pg. Marítim de la Barcelona, 25-29, Ciutat Vella, 08003 Barcelona, Spain
Research Overview
- Efficacy of Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Randomized Controlled Multicenter Study
- Efficacy and Safety of Immune-Guided Prophylaxis with Ganciclovir and Valganciclovir Hydrochloride in Low-Risk Renal Transplant Recipients
- Efficacy and Safety Evaluation of ALXN2030 in Antibody-Mediated Rejection Post-Kidney Transplantation: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 1 of 15 partner sites.
Specializations
Transplant Medicine
This investigator specializes in kidney transplantation with particular emphasis on managing post-transplant complications and rejection mechanisms.
- Antibody-Mediated Rejection (AMR)
- Graft Function Preservation
- Chronic Rejection Management
The research focus includes evaluation of novel therapeutic approaches for chronic active antibody-mediated rejection in transplant recipients.
Nephrology
The investigator's expertise centers on renal function assessment and monitoring in transplanted kidneys, with specific attention to long-term outcomes.
- Glomerular Filtration Rate Analysis
- Kidney Function Monitoring
- Long-term Graft Survival
Their work involves studying interventions that may improve graft function preservation in kidney transplant patients.
Immunotherapy
The investigator explores innovative immunological treatments for transplant recipients, focusing on combination therapy approaches.
- Novel Therapeutic Combinations
- Standard of Care Enhancement
- Immunological Response Modification
Their research examines the potential of combining different therapeutic agents to improve outcomes in transplant rejection cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.